Endo (ENDP) Beats On Q1 Earnings, Reaffirms '17 Guidance
Zacks Investment Research | May 09, 2017 02:07AM ET
Endo International plc’s (NASDAQ:ENDP) first-quarter 2017 earnings from continuing operations was $1.23 per share which topped the Zacks Consensus Estimate of $1.12. Earnings were also above the year-ago figure of $1.08.
Revenues came in at $1.03 billion in first-quarter of 2017, up 8% year over year, in line with the Zacks Consensus Estimate.
Shares of the company gained 6.9% following the release. However, we note that shares of Endo have underperformed the Zacks classified Medical-Drugs industry year to date. Specifically, the stock was down 34.1% during this period in comparison to industry’s gain of 3.3%.
Quarterly Highlights
The company reports results through three segments – Branded Pharmaceuticals (U.S.), Generic Pharmaceuticals (U.S.) and International Pharmaceuticals.
U.S. Branded Pharmaceuticals sales were down 19% to $250 million, reflecting generic entry for Voltaren Gel, Frova, Opana ER and Lidoderm, and divestiture of Stendra. Voltaren Gel sales were down 60% year over year to approximately $14.3 million. Sales of pain products Lidoderm and Opana ER were down 33% and 20%, respectively. However, Xiaflex sales increased 12% year over year reflecting double-digit demand growth for the product.
U.S. Generic Pharmaceuticals recorded sales of $722 million in the quarter, up 24% from the year-ago period owing to the launches of the generic version of Seroquel XR and Zetia. Segment revenues also benefited from the robust performance of sterile injectables. However, generics base business revenues declined approximately 32% due to increased competition and previously announced product discontinuances.
The International Pharmaceuticals division garnered sales of $65 million, down 8% year over year. Endo's previously announced divestiture of its South African subsidiary, Litha Healthcare Group to Acino Pharma (AG) is expected to close in the second quarter of 2017, subject to customary conditions. The company also announced that due diligence had begun on the potential divestiture of its Mexican subsidiary, Somar, which is in progress.
Get The News You Want
2017 Outlook
Endo reiterated its guidance for revenues and earnings per share for 2017. It expects revenues in the range of $3.45 billion to $3.60 billion. Also, the company projects continuing operations to be in the range of $3.45 to $3.75 per share. The Zacks Consensus Estimate for earnings is pegged at $3.63 per share on revenues of $3.55 billion.
Zacks Rank & Stocks to Consider
Endo currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the health care sector include Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) , Galena Biopharma, Inc. (NASDAQ:GALE) and BioTime, Inc. (NYSE:BTX) . While Infinity and Galena sport a Zacks Rank #1 (Strong Buy), BioTime has a Zacks Rank #2 (Buy). You can see .
Infinity’s loss per share estimates narrowed from $1.43 to $1.03 and from $1.75 to $1.52 for 2017 and 2016, respectively, over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 36.64%.
Galena’s loss per share estimates narrowed from $2.03 to 58 cents for 2017 over the last 60 days. The company posted positive earnings surprises in two of the four trailing quarters, with an average beat of 53.83%.
BioTime’s loss per share estimates narrowed 60.9% to 18 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in two of the four trailing quarters with an average beat of 12.32%. Its shares have increased 6.9% in the last year.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public. Starting today, for the next month, you can follow all Zacks' private buys and sells in real time.
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.